Saturday, October 20, 2018 7:09:03 PM
I would estimate the following timeline:
1. I assume they already wrote a protocol, if not add 2-4 weeks.
2. Site selection will be easy as there are probably only 12-20 possible sites for a phase 1 for Rett as the disease is too rare to go outside of one of the Rett Centers. For 15 patients they may only need 3 sites (range 1-5). They probably have the few sites already picked and the site selection (pre-study) visit can likely be skipped, replaced by a phone conference to review the final protocol. Each site will then need to turn in an application to an IRB. Theoretically, this process could be as fast as 2 weeks. However, academic centers usually insist that their own IRB be used instead of an independent IRB and that can add another month (or more). Then they can do the study initiation visits. Depending on whether all sites are synchronized with IRB approvals, this could be done at a common investigator meeting. If they just have one site that can use a central IRB, then this whole step could be 2 weeks but with several sites it will likely be 2 months to get all sites up.
3. I assume that all selected sites have "pre-screened" patients to identify those in general good health who have parents willing to comply with the protocols. The coordinator will need to inform the parents when they are ready to enroll. I start pre-screening for studies a month or so before they start so the coordinator can contact them as soon as we are cleared. So this could be as quick as a few days. Because PK/PD data is being selected and a couple blood draws may be needed day 1 and again at 24 and 48 hours, sites may not be able to enroll as rapidly as some believe. I think it will take a minimum of 2 months to get the 15 patients assuming 3 sites and would not be surprised if it took 4 months. The Neuren pediatric study took 5-6 months to enroll 82 patients at 12 sites. If they are up against Christmas they may wait to start until the New Year.
4. Add 7 weeks for the last patient to be out and are at 5-8 months for the first study so I agree with your estimate or summer 2019
5. They will need to then decide on details of the second study protocol based on results (minimum couple months analysis and protocol dessign) and 12 months minimum will be needed for site recruitment/IRB, patient recruitment, study and analysis. So best case would be 3Q2020 but early 2021 more likely.
1. I assume they already wrote a protocol, if not add 2-4 weeks.
2. Site selection will be easy as there are probably only 12-20 possible sites for a phase 1 for Rett as the disease is too rare to go outside of one of the Rett Centers. For 15 patients they may only need 3 sites (range 1-5). They probably have the few sites already picked and the site selection (pre-study) visit can likely be skipped, replaced by a phone conference to review the final protocol. Each site will then need to turn in an application to an IRB. Theoretically, this process could be as fast as 2 weeks. However, academic centers usually insist that their own IRB be used instead of an independent IRB and that can add another month (or more). Then they can do the study initiation visits. Depending on whether all sites are synchronized with IRB approvals, this could be done at a common investigator meeting. If they just have one site that can use a central IRB, then this whole step could be 2 weeks but with several sites it will likely be 2 months to get all sites up.
3. I assume that all selected sites have "pre-screened" patients to identify those in general good health who have parents willing to comply with the protocols. The coordinator will need to inform the parents when they are ready to enroll. I start pre-screening for studies a month or so before they start so the coordinator can contact them as soon as we are cleared. So this could be as quick as a few days. Because PK/PD data is being selected and a couple blood draws may be needed day 1 and again at 24 and 48 hours, sites may not be able to enroll as rapidly as some believe. I think it will take a minimum of 2 months to get the 15 patients assuming 3 sites and would not be surprised if it took 4 months. The Neuren pediatric study took 5-6 months to enroll 82 patients at 12 sites. If they are up against Christmas they may wait to start until the New Year.
4. Add 7 weeks for the last patient to be out and are at 5-8 months for the first study so I agree with your estimate or summer 2019
5. They will need to then decide on details of the second study protocol based on results (minimum couple months analysis and protocol dessign) and 12 months minimum will be needed for site recruitment/IRB, patient recruitment, study and analysis. So best case would be 3Q2020 but early 2021 more likely.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
